Mirati Therapeutics, Inc. (NASDAQ:MRTX) SVP Jamie Christensen sold 4,000 shares of the company’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $14.00, for a total value of $56,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jamie Christensen also recently made the following trade(s):

  • On Friday, September 15th, Jamie Christensen sold 770 shares of Mirati Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $9,240.00.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) traded down 2.68% on Friday, reaching $14.50. The company’s stock had a trading volume of 504,739 shares. The company’s market cap is $362.05 million. Mirati Therapeutics, Inc. has a 12 month low of $2.70 and a 12 month high of $15.40. The company has a 50-day moving average price of $8.21 and a 200 day moving average price of $5.17.

WARNING: This piece was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/mirati-therapeutics-inc-mrtx-svp-jamie-christensen-sells-4000-shares-of-stock/1616025.html.

Several institutional investors have recently bought and sold shares of MRTX. KCG Holdings Inc. acquired a new position in shares of Mirati Therapeutics during the 1st quarter worth $106,000. Susquehanna International Group LLP raised its holdings in shares of Mirati Therapeutics by 46.5% during the 2nd quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after buying an additional 16,030 shares in the last quarter. PDT Partners LLC acquired a new position in shares of Mirati Therapeutics during the 2nd quarter worth $200,000. Trexquant Investment LP raised its holdings in shares of Mirati Therapeutics by 62.2% during the 1st quarter. Trexquant Investment LP now owns 42,879 shares of the biotechnology company’s stock worth $223,000 after buying an additional 16,447 shares in the last quarter. Finally, LMR Partners LLP acquired a new position in shares of Mirati Therapeutics during the 2nd quarter worth $236,000. 60.17% of the stock is owned by institutional investors.

A number of research analysts recently commented on MRTX shares. Citigroup Inc. restated a “buy” rating and issued a $16.00 target price (up from $8.00) on shares of Mirati Therapeutics in a research note on Tuesday, September 19th. SunTrust Banks, Inc. restated a “buy” rating and issued a $13.00 target price on shares of Mirati Therapeutics in a research note on Monday, October 2nd. Jefferies Group LLC restated a “hold” rating and issued a $4.50 target price on shares of Mirati Therapeutics in a research note on Monday, June 12th. Leerink Swann upped their target price on Mirati Therapeutics from $7.00 to $9.00 and gave the company a “market perform” rating in a research note on Friday, September 15th. Finally, Cann began coverage on Mirati Therapeutics in a research note on Tuesday, September 19th. They set an “outperform” rating for the company. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $12.63.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.